Dapagliflozin in Type 2 Diabetes, HFrEF, and CKD
Indications
Dapagliflozin 10 mg once daily is indicated for this patient to simultaneously address all three conditions: chronic kidney disease progression, heart failure morbidity and mortality, and cardiovascular risk reduction. 1, 2
Chronic kidney disease: Dapagliflozin reduces the risk of sustained eGFR decline ≥50%, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with CKD at risk of progression when eGFR ≥25 mL/min/1.73 m². 1, 2
Heart failure with reduced ejection fraction: Dapagliflozin reduces cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure regardless of diabetes status. 1, 3, 2
Type 2 diabetes with cardiovascular risk: Dapagliflozin reduces the risk of heart failure hospitalization in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. 2
The drug provides benefit independent of diabetes status, with consistent efficacy demonstrated in patients both with and without type 2 diabetes across all three indications. 1, 3, 4
Starting Dose and Dose Titration
Initiate dapagliflozin at 10 mg orally once daily for cardiovascular and renal protection; no dose titration is required or recommended. 1, 2
For cardiovascular and renal indications (heart failure, CKD), the fixed dose is 10 mg once daily regardless of eGFR level (as long as ≥25 mL/min/1.73 m²). 1, 2
For glycemic control alone in patients with eGFR ≥45 mL/min/1.73 m², start at 5 mg once daily and may increase to 10 mg once daily if additional glucose lowering is needed. 1, 2
Do not reduce the dose below 10 mg for cardiovascular or renal indications, even at lower eGFR levels; all outcome trials used the fixed 10 mg dose. 1
No up-titration is needed for any cardiorenal indication, unlike ACE inhibitors, ARBs, or beta-blockers. 3
Contraindications
Absolute contraindications:
History of serious hypersensitivity reaction (anaphylaxis, angioedema) to dapagliflozin or any excipient. 2
eGFR <25 mL/min/1.73 m² for initiation (though continuation is permitted if eGFR falls below this threshold during treatment). 1, 2
Polycystic kidney disease or recent/current immunosuppressive therapy for kidney disease (dapagliflozin is not expected to be effective in these populations). 2
Relative contraindications and precautions:
Type 1 diabetes mellitus: Dapagliflozin significantly increases the risk of diabetic ketoacidosis in type 1 diabetes and is not recommended for glycemic control in this population. 2
Pregnancy and breastfeeding: Not recommended. 1
Dialysis dependence: Not indicated. 1
Pre-Initiation Assessment
Before starting dapagliflozin, perform the following assessments:
Measure eGFR to confirm ≥25 mL/min/1.73 m² for cardiovascular/renal indications (or ≥45 mL/min/1.73 m² if the primary goal is glycemic control). 1, 2
Assess volume status and correct any volume depletion before initiation; consider temporary reduction of concurrent loop or thiazide diuretics in patients at high risk for volume depletion (elderly, on diuretics, low systolic blood pressure). 1, 2
Check urine albumin-to-creatinine ratio (UACR): Strongest evidence for renal benefit exists when UACR ≥200 mg/g. 1
Exclude acute kidney injury by reviewing the timing of any recent creatinine increases and systematically ruling out prerenal (volume depletion, hypotension), intrinsic (nephrotoxic drugs, contrast, NSAIDs), or post-renal (obstruction) causes. 1
Monitoring Parameters
Initial monitoring (first 2–4 weeks):
Re-measure eGFR and creatinine 1–2 weeks after initiation. An acute, reversible eGFR dip of 2–5 mL/min/1.73 m² is expected and reflects hemodynamic changes rather than kidney injury; do not discontinue dapagliflozin in response to this expected dip. 1, 4, 5
Monitor blood glucose closely for the first 2–4 weeks, especially if insulin or sulfonylureas are still being used; reduce insulin dose by ~20% and discontinue sulfonylureas when baseline HbA1c is <8.5%. 1
Re-assess volume status at follow-up, with particular attention to elderly patients or those on diuretics. 1
Ongoing monitoring:
Recheck eGFR at least every 3–6 months if eGFR is 45–59 mL/min/1.73 m², or annually if eGFR ≥60 mL/min/1.73 m². 1
Monitor for genital mycotic infections (occur in ~6% of patients vs. 1% with placebo); advise daily hygiene to reduce risk. 1, 3
Monitor for urinary tract infections (2.3–2.7% incidence). 3
Educate patients about euglycemic diabetic ketoacidosis and instruct them to seek immediate care for unexplained malaise, nausea, vomiting, or abdominal pain even when blood glucose is normal. 1, 3
Medication Adjustments
When adding dapagliflozin to existing therapy:
Continue ACE inhibitors or ARBs unchanged when dapagliflozin is started; >99% of DAPA-CKD participants were on renin-angiotensin-aldosterone system blockers, and the combination showed additive renal protection without dose adjustments. 1
Reduce insulin dose by ~20% when baseline HbA1c is <8.5% to mitigate hypoglycemia risk. 1
Discontinue sulfonylureas (e.g., glipizide, gliclazide) when starting dapagliflozin; the combination increases hypoglycemia risk without adding cardiovascular benefit. 1
Consider reducing concurrent loop or thiazide diuretic doses at initiation to avoid excessive volume depletion, especially in elderly patients. 1
If metformin is being used and eGFR is 30–44 mL/min/1.73 m², continue metformin but limit the dose to ≤1000 mg per day. 1
Sick Day Management and Temporary Interruption
Withhold dapagliflozin during:
Acute illness with reduced oral intake, fever, vomiting, or diarrhea to prevent diabetic ketoacidosis and volume depletion. 1, 4, 2
At least 3 days before major surgery or procedures requiring prolonged fasting. 1, 2
Hospitalization for intercurrent illness until the patient has recovered and normal oral intake is re-established. 1
Patient education on sick day rules:
Instruct patients to stop dapagliflozin immediately when they become sick and contact their healthcare provider. 1
Maintain at least low-dose insulin in insulin-requiring individuals even when dapagliflozin is held; complete insulin cessation increases DKA risk. 1
Resume dapagliflozin only after recovery from acute illness and re-establishment of normal oral intake. 1
Common Pitfalls to Avoid
Do not discontinue dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m²; cardiovascular and renal benefits persist despite loss of glycemic efficacy. 1, 4
Do not stop dapagliflozin in response to the expected early eGFR dip (2–5 mL/min/1.73 m² within the first 2–4 weeks); the change is hemodynamic and reversible, not indicative of kidney injury. 1, 4, 5
Do not reduce the dapagliflozin dose below 10 mg for cardiovascular or renal indications, even at lower eGFR levels; all outcome trials used the fixed 10 mg dose. 1
Do not combine dapagliflozin with sulfonylureas when baseline HbA1c is <8.5%, as the combination raises hypoglycemia risk without adding cardiovascular benefit. 1
Do not withhold ACE inhibitors or ARBs when starting dapagliflozin; the combination provides additive renal protection. 1
Alternative Therapies
If dapagliflozin cannot be used (e.g., eGFR <25 mL/min/1.73 m², contraindication, intolerance):
Empagliflozin (10 mg once daily) or canagliflozin (100 mg once daily) provide similar cardiorenal benefits and may be preferred based on formulary coverage. 1, 3
GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, semaglutide) can be considered for patients with eGFR >30 mL/min/1.73 m², providing additional cardiovascular protection and glycemic control without dose adjustment. 1
Insulin therapy remains fully effective regardless of kidney function and can be used as the primary glucose-lowering agent when aggressive glycemic control is required. 1
DPP-4 inhibitors (e.g., linagliptin) can be used without dose adjustment at any eGFR level, though they lack the robust cardiorenal benefits of SGLT2 inhibitors and GLP-1 receptor agonists. 1
Evidence-Based Clinical Benefits
Renal outcomes (DAPA-CKD trial):
39% reduction in the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or cardiovascular/renal death (HR 0.61,95% CI 0.51–0.72). 1, 6
44% reduction in kidney-specific composite outcome (sustained eGFR decline, end-stage renal disease, or renal death; HR 0.56,95% CI 0.45–0.68). 1, 6
Slows the rate of eGFR decline over time and reduces progression to end-stage renal disease. 1, 5
Cardiovascular outcomes:
29% reduction in cardiovascular death or heart failure hospitalization (HR 0.71,95% CI 0.55–0.92). 1, 6
31% reduction in all-cause mortality (HR 0.69,95% CI 0.53–0.88). 1
26% reduction in the composite of cardiovascular death or worsening heart failure in HFrEF patients (DAPA-HF trial). 3, 6
Benefits occur within weeks of initiation and are maintained regardless of age, sex, or background medical therapy. 3